NCT02950948View on ClinicalTrials.gov

Progesterone in Luteal Phase Deficiency

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 3, 2017

Primary Completion Date

March 31, 2019

Study Completion Date

December 31, 2019

Conditions
Luteal Phase Defect
Interventions
DRUG

Progesterone

Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.

DRUG

Placebo

A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.

Sponsors
All Listed Sponsors
lead

IBSA Institut Biochimique SA

INDUSTRY

NCT02950948 - Progesterone in Luteal Phase Deficiency | Biotech Hunter | Biotech Hunter